Literature DB >> 27291974

Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail.

Ching Kim Tye1, Zhanbin Wang2, Randy C Dockens3, Blisse Vakkalagadda3, Chunlei Wang4, Yingru Zhang4, Ching Chiang Su2, Michael J Hageman2.   

Abstract

A comprehensive 8-drug metabolic cocktail was designed to simultaneously target 6 Cytochrome P450 enzymes and 2 membrane transporters. This study aimed to assess the pre-absorption risk of this new metabolic cocktail which contained metoprolol, caffeine, midazolam, pravastatin, flurbiprofen, omeprazole, digoxin and montelukast. This paper describes a systematic approach to understand whether the co-administration of the 8 selected drug products, i.e., the physical mixing of these products in the human gastro-intestinal environment, will create any issue that may interfere with the individual drug dissolution which in turns modify the total amount or timing of their availability for absorption. The evaluation consisted of two steps. An initial evaluation was based on theoretical understanding of the physicochemical properties of the drugs and the gastro intestinal environment, followed by in vitro dissolution tests. The results indicated that the designer 8-drug cocktail has acceptable pre-absorption compatibility when dosed simultaneously, and recommended the progression of the cocktail into clinical validation study.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Caffeine (PubChem CID: 2519); Co-administration; Digoxin (PubChem CID: 2724385); Flurbiprofen (PubChem CID: 3394); Metabolic cocktail; Metoprolol (PubChem CID: 11957594); Midazolam (PubChem CID: 4192); Montelukast (PubChem CID: 5281040); Omeprazole (PubChem CID: 4594); Physicochemical interaction; Pravastatin (PubChem CID: 16759173)

Mesh:

Substances:

Year:  2016        PMID: 27291974     DOI: 10.1016/j.ijpharm.2016.06.028

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.

Authors:  Tushar Garimella; Xiaolu Tao; Karen Sims; Yi-Ting Chang; Jignasa Rana; Elsa Myers; Megan Wind-Rotolo; Rahul Bhatnagar; Timothy Eley; Frank LaCreta; Malaz AbuTarif
Journal:  Drugs R D       Date:  2018-03

2.  Rational formulation engineering of fraxinellone utilizing 6-O-α-D-maltosyl-β-cyclodextrin for enhanced oral bioavailability and hepatic fibrosis therapy.

Authors:  Jianbo Li; Tiange Feng; Weijing Yang; Yaru Xu; Shuaishuai Wang; Huijie Cai; Zhilei Liu; Hong Qiang; Jinjie Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.